WHO Expands Genetic Evidence for Drug-Resistant Tuberculosis
A revised mutation catalogue could help laboratories interpret faster tests, but unequal access to diagnosis and treatment remains a major obstacle.
The World Health Organization has expanded its global reference for identifying drug-resistant tuberculosis through genetic testing, reflecting growing evidence about how particular bacterial mutations affect treatment options.
The third edition of WHO’s mutation catalogue, published November 10, draws on more than 71,000 clinical isolates from over 75 countries. That represents 37% more isolates and 12% greater country coverage than the previous edition in 2023.
The update is an important technical resource, not a new drug or a guarantee of faster treatment. Laboratories still need diagnostic equipment, trained staff and access to effective medicines before the catalogue’s expanded evidence can improve care.
Why a mutation catalogue matters
Tuberculosis bacteria can develop resistance to medicines used for treatment. Conventional culture-based testing may take time, while molecular and sequencing-based methods seek genetic signals associated with whether particular drugs will work.
The catalogue helps laboratories interpret those signals consistently, identifying variants backed by evidence of resistance or susceptibility. Without agreed standards, the same sequencing result might be treated differently across countries or testing platforms.
WHO says the revised edition also strengthens evidence for newer and repurposed medicines, including pretomanid and cycloserine. It updates statistical methods and offers a graded interpretation framework designed to reduce uncertainty in decisions based on genetic data.
More data, practical questions
Larger datasets can improve classification, but the distribution of samples matters. Resistant strains and genetic backgrounds vary across regions, and even an extensive catalogue may not represent every setting equally.
Laboratories must also maintain quality controls and make sure that new sequencing methods perform reliably outside specialist centres. Test accuracy is one part of implementation; turnaround time, sample transport and the ability to change therapy promptly are equally important.
WHO’s guidance on generating evidence for new TB diagnostics, published in October, calls for studies that examine feasibility, equity, acceptability and costs rather than accuracy alone. That broader focus reflects the difference between an impressive laboratory result and a public-health tool that patients can actually use.
Access remains a constraint
Drug-resistant tuberculosis continues to present a serious challenge. WHO reports that fewer than half of affected people have access to treatment, underscoring the size of the gap between technical capabilities and health-system delivery.
New near point-of-care testing approaches and alternative sample types may help reach people who cannot produce sputum or access centralized laboratories. Yet services require trained clinicians, dependable purchasing systems and follow-up for patients whose treatment must change.
For lower-income health systems, sequencing capacity may need to be shared through referral networks. Establishing advanced equipment in every local clinic may not be financially or technically sustainable.
A test of implementation
Governments and developers should track whether genomic testing reduces delays in appropriate therapy and improves outcomes, not just how many samples are sequenced. Procurement and training plans should be matched to the drugs available.
The expanded WHO catalogue is a valuable foundation for more consistent interpretation. Its public-health impact will depend on whether countries turn that knowledge into accessible diagnostic services and prompt treatment for people with drug-resistant tuberculosis.
A second concern is data governance. Genetic information from bacterial samples needs standardized handling and secure, appropriate sharing across laboratories. Public health programs must balance the benefits of international comparison with privacy safeguards and local requirements. Stronger data systems can make surveillance more useful without making individual patients identifiable.
